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Abstract 
Introduction: The aim of the study was to evaluate some selected parameters of the antioxidative system in patients with type
2 diabetes. 
Materials and Methods: Eighty-one type 2 diabetes patients took part in the study (39 patients with metabolically balanced and
42 with metabolically unbalanced diabetes). The control group consisted of 30 healthy people. The total antioxidant capacity of
plasma was measured fluorometrically using phycoerythrin. To calculate the low-molecular-weight antioxidant concentration in
the plasma samples, the duration of Trolox activity as a function of its concentration in the sample was measured. The activity
of antioxidative enzymes in red blood cells was determined using the Misra and Fridovich method and Beers and Sizer method. 
Results: The total plasma antioxidant capacity and the low-molecular-weight antioxidant concentration in the group of
patients with metabolically compensated type 2 diabetes were statistically significantly higher than in the group of patients
with metabolically uncontrolled diabetes. The activity of antioxidative enzymes was found to be higher in the group of type
2 diabetes patients at the stage of metabolic balance. 
Conclusions: The obtained results confirm the thesis of glucose toxicity and intensification of oxidative stress in patients with
diabetes.
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INTRODUCTION
Oxidative stress is a state characterized by increased
activity of reactive oxygen species (ROS). Its development
is a consequence of a pro-oxidative disturbance in the oxi-
dation-reduction balance [18, 38, 39]. Although the human
body is capable of free radical inactivation under physio-
logical conditions, a major balance upset in the system of
oxidants and antioxidants leads to a breakdown of cell and
tissue integrity and the chemical modification of proteins,
nucleic acids, lipids, and carbohydrates [2, 20, 23, 33, 37]. 
The effects of ROS influence may be varied. They
lead, among other things, to the oxidation of low-mole-
cular-weight compounds (glutathione, nicotinamide-
adenine nucleotides), collagen degradation, hyaluronic
acid depolymerization, hemoglobin oxidation, protein
transport, and enzyme inactivation [4, 5, 19, 34]. ROS
are also responsible for DNA strand breaks, chromo-
some damage, membrane lipid peroxidation, inhibition
of oxidative phosphorylation in mitochondria, perturba-
tion of intracellular Ca2+ homeostasis, platelet aggrega-
tion, and lipid peroxidation [30].
In the course of evolution, organisms have developed
some more or less refined mechanisms protecting them
against the harmful activity of free radicals, both in enzy-
matic and non-enzymatic ways [1, 13, 30, 32]. Theseinclude a number of enzymes which directly catalyze
reactions involving ROS, such as superoxide dismutase
(SOD), glutathione peroxidase, and catalase (CAT), as
well as enzymes which catalyze these reactions indirect-
ly, e.g. glutathione transferase and glucose-6-phosphate
dehydrogenase. Low-molecular-weight compounds,
defined as low-molecular-weight antioxidants, also play
an important role in maintaining the oxidation-reduction
balance. The most important low-molecular-weight
antioxidants are glutathione, ascorbate, and vitamin E.
A number of other compounds, such as cysteine, uric
acid, bilirubin, and catecholamines, are also known
antioxidants [1, 30, 32]. Although extracellular fluids do
not show much antioxidant capacity, they contain both
antioxidative enzymes and low-molecular-weight antiox-
idants. The activity of antioxidative enzymes in plasma is
low compared with their intracellular activity, but plasma
contains a number of low-molecular-weight antioxidants,
the most important of which is ascorbate, which reacts
with superoxide anion radical, hydrogen peroxide, per-
oxide radicals, and singlet oxygen. Other antioxidants
are, for example, tocopherols, carotenoids, and uric acid.
Growing attention has been paid to the participation
of ROS in the pathomechanisms of many diseases,
including diabetes. It was observed that in the course of
diabetes an intensification of oxidative stress takes place,
with considerable predominance of oxidative factors over
antioxidative mechanisms [30]. As in other diseases,
oxidative stress in diabetes is a result of increased ROS
production on the one hand and decreased antioxidant
system activity on the other. The evaluation of antioxida-
tive enzyme activity in this disease is controversial. In
experimental studies, both declines in antioxidative
enzyme activity, e.g. glutathione peroxidase, and increas-
es in the activities of other key cellular antioxidative
enzymes, i.e. SOD and CAT in kidney of rats with strep-
tozotocin-induced diabetes, were described [4, 21, 22]. In
red blood cells from patients with diabetes, an increased
amount of the glycated form of SOD accompanied by
a lower activity of this enzyme [27, 29] was observed. It
was shown in some experimental and clinical studies that
intensification of ROS production depends not only on
the degree of diabetes compensation, but also on its dura-
tion [3]. The aim of this study was therefore to evaluate
some selected parameters of the antioxidative system in
patients with type 2 diabetes, both controlled and uncon-
trolled, by determining the activity levels of antioxidative
enzymes such as SOD and CAT in the patients’ red blood
cells and the total antioxidant capacity and concentration
of low-molecular-weight antioxidants in plasma.
MATERIALS AND METHODS
Patients population
Eighty-one patients with diabetes mellitus (28 women
[34.6%], 53 men [65.4%]) with a mean age of 63.4±9.7
years were included to the study. The mean duration of
the disease was over 14±1.2 years. Because of difficulties
in choosing suitable people for the control group compa-
rable in terms of age and sex to the examined patients and
not taking drugs with known antioxidative properties or
drugs potentially influencing cellular metabolism, arefer-
ence group (C) consisting of 30 healthy people (mean
age: 47.1±8.2 years), who were arepresentative group for
the given region, was formed. Permission to carry out the
study was granted by the Ethics Committee of Medical
University of £ódŸ, Poland (No. 139/01). 
All the participants of the study underwent a subjec-
tive and an objective examination and they also had
their blood tested with respect to blood glucose level,
total cholesterol, triglycerides, plasma creatinine, and
glycosylated hemoglobin level. All the examined per-
sons had their body mass index calculated. The precon-
dition for participation in the study was not taking drugs
with recognized antioxidative properties. The partici-
pants were non-smokers and were also on a diabetic diet
excluding foods with recognized antioxidative proper-
ties. Patients qualified for the study were consulted by
a nephrologist, an ophthalmologist, and a vascular sur-
geon to exclude micro- and macroangiopathy (Table 1).
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Table 1. The clinical characteristics of investigated patients
DMC DMU C
Number of patients 39 42 30
Mean age (x±SD) 64.3±9.8 62.7±10.2 47.1±8.2
HbA1c (%) 6.7±1.3 8.0a±1.7 5.7±1.1
BMI (kg/m2) 23.8±3.7 25.4±3.8 21.9±2.8
Total cholesterol (mmol/l) 5.8±1.4 6.5b±1.4 4.5±1.1
LDL-cholesterol (mmol/l) 2.18±1.1 3.11b±1.3 2.13±0.9
HDL-cholesterol (mmol/l) 1.41±0.6 1.21b±1.1 1.36±1.2
Triglyceride (mmol/l) 1.8±0.7 2.4 b±1.2 1.2±0.4
Glucose (mmol/l) 7.8±1.7 9.3 a±1.5 4.8±1.5
Creatynine (µmol /l) 88.5±20.3 89.1b±23.4 86.7±14
Albumin secretion (mg/24 h) 10.8±2.6 11.7 b±2.5 8.3±1.9
DMC – patients with metabolically compensated type 2 diabetes, DMU – patients with metabolically
uncontrolled type 2 diabetes, C – control, BMI – body mass index. 
ap<0.05 C vs. DMU, DMC, bp>0.05 C vs. DMU, DMC.The fundamental criterion for inclusion in the study
was diagnosed and documented type 2 diabetes. The
examined patients were divided into two groups on the
basis of the criteria of diabetes compensation formulat-
ed by the European Association for the Study of
Diabetes: patients with metabolically compensated type
2 diabetes and patients with metabolically uncontrolled
type 2 diabetes (Table 1). 
Experimental procedures
The blood samples for the tests were collected (after
an overnight fast, before the administration of morning
hypoglycemic drugs) in heparin tubes from the basilic
vein (250 units heparin/1 ml blood) and were then cen-
trifuged (1400×g, 4°C, 10 min). The total antioxidant
capacity and low-molecular-weight antioxidant concen-
tration were determined in the resulting plasma. The
total antioxidant capacity of plasma was measured fluo-
rometrically using phycoerythrin [17]. To calculate the
low-molecular-weight antioxidant concentration in
a plasma sample, the duration of Trolox activity as
a function of its concentration in the sample was mea-
sured. The activity of SOD in red blood cells was evalu-
ated by the method of Misra and Fridovich [29]. The
activity of the enzyme was determined based on the
inhibition of the adrenaline peroxidation reaction by
dismutase in which the superoxide anion radical takes
part. The activity of CAT was evaluated by the method
of Beers and Sizer [6], based on measurement of the
rate of hydrogen peroxide decomposition caused by this
enzyme.
Statistical analysis
As the number of persons was different in each
group and deviation of the examined variables from the
normal distribution was found using the Leven and
Kolmogorov-Smirnoff tests, comparisons of the vari-
ables were based on non-parametric tests, mainly of the
median (Mann-Whitney-U, Kruskall-Wallis ANOVA).
A value of p<0.05 was taken to represent a statistical
significance level for all the tests and analyses.
RESULTS
The concentration of glycated hemoglobin was sta-
tistically significantly higher in the group of patients
with metabolically uncontrolled type 2 diabetes than in
the control group and the group of patients with meta-
bolically compensated type 2 diabetes (Table 1).
In both groups of patients with diabetes, both the
total antioxidant capacity of plasma and low-molecular-
weight antioxidant concentration were statistically sig-
nificantly lower compared with the reference group
(p<0.05). Total plasma antioxidant capacity and low-
molecular-weight antioxidant concentration in the
patients with metabolically compensated type 2 diabetes
were statistically significantly higher than in the patients
with metabolically uncontrolled diabetes (p<0.05;
Tables 2 and 3).
Comparing the activity of SOD in the two groups of
patients with type 2 diabetes, higher activity of the enzyme
was observed in the patients with type 2 diabetes in the
period of metabolic compensation. The differences
between the activity in this group of patients and the
group with diabetes in the period of metabolic decompen-
sation were statistically significant (p<0.05). Comparing
the values of SOD activity in the groups of patients with
type 2 diabetes with the reference group, a statistically sig-
nificant decrease in activity (p<0.05) was observed in the
group of patients with type 2 diabetes (Table 4). 
Statistically significantly higher CAT activity in the
group of patients in the period of metabolic compensa-
tion than in the group with decompensation of diabetes
was observed (p<0.05; Table 5). However, comparing
the average CAT activities in both groups of patients
with that in the reference group, a statistically signifi-
cantly lower activity of CAT in both groups with type 2
diabetes (p<0.05) was observed (Table 5).
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Table 2. The total antioxidant capacity of plasma (min)
Mean Median Minimal Maximal SD
C 16.5 12.9 10.5 18.5 1.70
DMC 12.5a 10.2 9.5 13.0 1.61
DMU 9.0a, b 8.3 6.5 10.0 0.86
ap<0.05 C vs. DMC DMU, 
bp<0.05 DMC vs. DMU.
Table 3. The concentration of low-molecular-weight antioxi-
dants in plasma (µmol/ml)
Mean Median Minimal Maximal SD
C 687.3 642.4 594.4 842.3 84.4
DMC 584.4a 542.3 487.0 671.3 71.1
DMU 468.2 a, b 398.1 324.3 521.2 63.0
ap<0.05 C vs. DMC, DMU, 
bp<0.05 DMC vs. DMU.
Table 4. SOD-1 activity in red blood cells (U/gHb)
Mean Median Minimal Maximal SD
C 2394.2 2245.2 2134.1 2451.4 203.0
DMC 2156.0a 2034.0 1985.6 2211.2 158.8
DMU 1979.8a, b 1884.4 1798.7 2054.3 123.1
ap<0.05 C vs. DMC, DMU, 
bp<0.05 DMC vs. DMU.
Table 5. CAT activity in red blood cells (U Bergmeyer/gHb)
Mean Median Minimal Maximal SD
C 18.4 17.1 16.5 19.8 1.7
DMC 15.5a 15.0 14.2 17.1 1.7
DMU 12.2a, b 11.1 10.6 13.4 1.0
ap<0.05 C vs. DMC, DMU, 
bp<0.05 DMC vs. DMU.DISCUSSION
Oxidative stress in diabetes, as in other ailments, is
a result of the hyperproduction of reactive oxygen forms
on the one hand and hypoactivity of the antioxidative
system on the other. Long-term hyperglycemia may be
an initializing factor for the systemic oxidative stress in
diabetes. Ceriello’s thesis about “glucose toxicity” [12]
confirms this assertion. Intensified ROS generation
induced under conditions of increased glucose concen-
tration is an effect of increased activity of several inde-
pendent metabolic pathways, such as monosaccharide
autooxidation, non-enzymatic glycation intensification,
protein kinase C (PKC) and phospholipase A2 activa-
tion, and increased activation of the intracellular polyol
pathway [6, 9, 15, 16, 24, 28]. Besides the increased pro-
duction of ROS in diabetes, revealed indirectly by inten-
sified lipid peroxidation, weakening of defensive mech-
anisms also upsets the oxidation-reduction balance. The
systemic defense functions against oxidative damage are
performed by two antioxidative systems: enzymatic and
non-enzymatic. Their task is to prevent the formation of
ROS as well as to scavenge existing ROS [35].
Many studies, both clinical and experimental,
showed changes in the activities of enzymatic antioxida-
tive systems in the course of diabetes. However, there
are large discrepancies in evaluations of the activities of
these enzymes in patients with diabetes. Both increases
and decreases in antioxidative enzyme activity in animal
experimental models were observed [20]. In our previ-
ous research, a decrease in the activities of key cellular
antioxidative enzymes in the erythrocytes of patients
with diabetic nephropathy was observed [36].
In the current study, statistically significantly higher
SOD activity in the group of patients with metabolically
compensated type 2 diabetes than in the patients with
improper metabolic control was observed. Comparing
the obtained values of SOD activity in each group of
patients with type 2 diabetes in different periods of
metabolic compensation to the reference group, a sig-
nificant decrease in the activity of the enzyme was
observed, especially in patients with improper metabol-
ic diabetes control. A lowering of SOD activity has been
reported in some previous publications. Matkovics et al.
[28] were the first to suggest an association of lowered
SOD activity with diabetes. Crouch et al. [16] showed
that in experimental diabetes in rats, the activity of SOD
in red blood cells and in the retina was decreased by
50% in comparison with healthy animals. Kawamura et
al. [24] found an increased amount of the glycated form
of SOD in the erythrocytes of patients with type 1 dia-
betes, which was connected with the lowered activity of
this enzyme. 
As for the second antioxidant enzyme studied, CAT,
the lowest activity was also found in the group of
patients with metabolically uncontrolled diabetes.
Comparing the average values of CAT activity in both
groups of patients to that in the reference group, low-
ered CAT activity in the groups of patients with meta-
bolically uncontrolled type 2 diabetes was observed.
This observation was confirmed in our previous experi-
mental research, in which lowered CAT activity was
observed both in erythrocytes and in kidney
homogenate of rats with streptozotocin-induced dia-
betes [26]. The lowered CAT activity may be a result of
increased superoxide anion radical production and
a surCATus of hydrogen peroxide, which occurs under
conditions of an increased glucose concentration in
plasma. Superoxide anion radical is an inhibitor of CAT
and hydrogen peroxide may be a precursor of other
ROS, which may in turn initiate processes of lipid per-
oxidation, as was shown, among others, by Salahudeen
et al. in their papers [35, 36]. The decreased CAT activ-
ity observed in our own and other authors’ research con-
firms that this enzyme may easily get inactivated as
a result of ROS influence, especially under conditions of
improper metabolic control and long-term hyper-
glycemia. 
The hyperglycemia associated with diabetes and its
complications may result in a deficiency or decline in the
activity of plasmatic antioxidants, such as α-tocopherol,
uric acid, ferritin, albumin, and ascorbic acid, and in
a decline in the activity of plasmatic antioxidative
enzymes. Although extracellular fluids do not show high
antioxidant capacity, they contain both antioxidative
enzymes and low-molecular-weight antioxidants. The
activity of antioxidative enzymes in plasma is low in
comparison with their intracellular activity; however,
plasma contains several low-molecular-weight antioxi-
dants. One of the more important antioxidants is an
ascorbate active in the watery environment of the body
and reactive with superoxide anion radical, hydrogen
peroxide, peroxide radicals, and singlet oxygen. It plays
an important role in protecting protein thiol groups
from oxidation. Other important plasmatic antioxidants
are well as tocopherols are associated with lipoproteins
which scavenge organic free radicals and break the reac-
tion of lipid peroxidation. Carotenoids suppress singlet
oxygen and react with organic free radicals created dur-
ing the process of lipid peroxidation. Uric acid reacting
with oxidants and combining with iron ions also plays an
vital role here [11].
In our previous research, significant declines in the
concentrations of such antioxidative vitamins as vitamin
C and E in the plasma of rats with streptozotocin-
induced diabetes were observed. It was connected with
lowered activity of cellular antioxidative enzymes and an
intensification of lipid peroxidation processes in the kid-
neys of the examined animals. Moreover, a thickening
of the basal membrane in the renal glomeruli was
observed in these rats [25, 26]. Decreased concentra-
tions of vitamin C in the plasma and tissue of patients
with diabetes and in animals with experimental diabetes
were also observed by other researchers [36]. It was also
revealed that antioxidative vitamin C and E supplemen-
tation inhibits increased TGF-β secretion in the renal
glomeruli of rats with diabetes by lowering the activity of
PKC [18, 20, 38]. A lowering of oxidative stress intensi-
J. Rysz et al.: Antioxidative system in diabetes 338ty and an improvement in the examined morphometric
parameters of the renal glomeruli after 12 weeks of vit-
amin C and E supplementation were also observed in
our previous research [11, 26]. 
In the diabetic patients of the present study, higher
antioxidant capacity of plasma, expressed by the time of
free radical inactivation by the antioxidant system in
plasma, was observed in those with metabolically com-
pensated diabetes. Moreover, a higher concentration of
low-molecular-weight antioxidants was observed in the
patients with metabolically compensated diabetes than
in the group with improper metabolic control. However,
comparing the total antioxidant capacity of plasma and
the concentration of low molecular-weight-antioxidants
in each group of patients with diabetes to the reference
group, statistically significantly lower values of these
parameters were found in the patient groups.
Considering both our own and other authors’ results, an
hypothesis stating that the intensity of oxidative stress
depends, among other things, on the duration of the dis-
ease as well as on the metabolic compensation may be
formulated [7, 8, 10, 14]. This is also confirmed by pre-
vious research in which a statistically significantly low-
ered activity of the key antioxidative enzymes in red
blood cells of patients with type 2 diabetes was
observed; the lowest activity of these enzymes was
observed in patients with diabetic nephropathy.
The results of the examined parameters of the
antioxidative system in diabetes show that patients with
metabolically uncontrolled diabetes have reduced
antioxidative enzyme activity, plasma antioxidant con-
centration, and total plasma antioxidant capacity. As
mentioned above, diabetes is accompanied by systemic
oxidative stress. Glucose, with an aldehyde group in its
molecule, reacts with the encountered amino groups. As
the result of this reaction the proteins undergo a non-
-enzymatic glycosylation, which leads to the formation
of the advanced glycation endproducts. Furthermore,
what has also mentioned above, the hyperactivity of the
generation of ROS evoked by elevated glucose concen-
tration is also an effect of the hyperactivity of some
independent metabolic pathways such as monosaccha-
ride autooxidation, the extent of non-enzymatic glycosy-
lation, PKC activation and phospholipaseA2, and hyper-
activity of the intracellular polyol pathway [24, 28].
The observed disorders in the antioxidant protective
system of erythrocytes of patients with type 2 diabetes
may indicate a higher susceptibility of “diabetic” ery-
throcytes to oxidative stress. These disorders are greater
with metabolically unbalanced diabetes, which found
confirmation in our studies. The elevated concentration
of glycolated hemoglobin in diabetes, especially when
the ailment is improperly controlled, may not only
evoke an increase in oxidative stress, but it may also
effect oxidative erythrocyte damage and the rheological
changes that go with it, which may then lead to the
development of vascular complications in diabetes.
An increased concentration of total cholesterol and
triglycerides may have an influence on lowering the
activity of the antioxidative system in patients with
metabolically unbalanced type 2 diabetes; however, the
differences in the values of these parameters in the two
groups of diabetic patients were not statistically signifi-
cant. The mechanism and relationships in the oxidative-
antioxidative system of this group of examined patients
would perhaps have been more comprehensible if the
lipid peroxidation products or the ATP concentration in
erythrocytes had been determined, because one of the
after-effects of intensified exposure of cells to oxidative
stress is lowered ATP level; however, this requires fur-
ther and broader studies [31]. 
In conclusion, the obtained results confirm the the-
sis of glucose toxicity and intensification of oxidative
stress in diabetes. Long-term hyperglycemia leads,
through the activation of various metabolic pathways, to
an intensification of free radical processes and a weak-
ening of antioxidative mechanisms.
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